PharmacyCodes



Ergoloid Mesylates [Usan] en es it fr

Ergoloid Mesylates [Usan] Brand names, Ergoloid Mesylates [Usan] Analogs

Ergoloid Mesylates [Usan] Brand Names Mixture

  • No information avaliable

Ergoloid Mesylates [Usan] Chemical_Formula

C33H45N5O5

Ergoloid Mesylates [Usan] RX_link

No information avaliable

Ergoloid Mesylates [Usan] fda sheet

Ergoloid Mesylates [Usan] msds (material safety sheet)

Ergoloid Mesylates [Usan] Synthesis Reference

No information avaliable

Ergoloid Mesylates [Usan] Molecular Weight

591.741 g/mol

Ergoloid Mesylates [Usan] Melting Point

No information avaliable

Ergoloid Mesylates [Usan] H2O Solubility

No information avaliable

Ergoloid Mesylates [Usan] State

Solid

Ergoloid Mesylates [Usan] LogP

2.615

Ergoloid Mesylates [Usan] Dosage Forms

Capsule; Liquid; Powder; Powder for solution; Solution; Syrup; Tablet

Ergoloid Mesylates [Usan] Indication

For use as an adjunct therapy for patients with dementia

Ergoloid Mesylates [Usan] Pharmacology

Ergoloid Mesylate may increase cerebral metabolism and blood flow. The role of this medication in the therapy of dementia is controversial. A recent controlled study in patients with Alzheimer's disease found that there was no advantage to the use of ergoloid mesylates compared to placebo, suggesting that ergoloid mesylates may lower scores on some cognitive and behavioral rating scales. Further study is needed to determine the risk-benefit profile of ergoloid mesylates in the treatment of dementia.

Ergoloid Mesylates [Usan] Absorption

Rapidly but incompletely (approximately 25%) absorbed from the gastrointestinal tract. Approximately 50% of the absorbed dose is eliminated by first-pass metabolism.

Ergoloid Mesylates [Usan] side effects and Toxicity

Symptoms of overdose include dyspnea, hypotension or hypertension, rapid weak pulse, delirium, nausea, vomiting, and bradycardia.

Ergoloid Mesylates [Usan] Patient Information

No information avaliable

Ergoloid Mesylates [Usan] Organisms Affected

Humans and other mammals